Scribe Therapeutics filed a 424B4 prospectus for its initial public offering on the Nasdaq Global Market under the ticker SCTX. The company is offering 8,580,000 shares at $15.00 per share, for gross proceeds of $128.7 million, with a 30-day option for underwriters to purchase up to 1,287,000 additional shares. In a concurrent private placement, Sanofi agreed to purchase 500,000 shares at the IPO price.

Business Description

Scribe Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines designed to deliver durable, preventive treatment for common cardiometabolic diseases. The company has engineered two proprietary CRISPR platforms: ELXR, an epigenetic silencing technology intended to durably repress disease-causing genes without altering DNA, and XE, a gene-editing system designed for precise, efficient modification with high specificity. Scribe’s lead product candidate, STX-1150 (ELXR targeting PCSK9), aims to provide long-lasting LDL-C reduction without permanent DNA changes and has entered a first-in-human trial in Australia. Early non-human primate studies of a prototype showed >50% LDL-C reductions sustained for two years after a single dose.

Beyond LDL-C, Scribe is advancing STX-1200 (XE targeting LPA) to address elevated Lp(a), a major genetic driver of cardiovascular risk affecting roughly 20% of the global population, and STX-1400 (XE targeting APOC3) to reduce triglycerides and pancreatitis risk, with potential expansion to broader ASCVD prevention. The company supports development with its CRISPR by Design approach, coupling machine learning with extensive experimental validation. Scribe also has strategic collaborations with Sanofi (in vivo therapies including sickle cell disease) and Lilly/Prevail (neurological and neuromuscular disorders), plus a manufacturing and delivery ecosystem that includes Acuitas LNP technology and CIRM grant support.

Market Overview

  • Total addressable market: LDL-C–lowering market exceeds $5 billion annually; ASCVD costs were $422 billion in 2019–2020 in the U.S. and are projected to reach $1.8 trillion by 2050.
  • Market growth: ASCVD prevalence expected to rise due to aging demographics and worsening metabolic health; significant underpenetration of advanced lipid-lowering therapies.
  • Market position: Scribe is developing durable, in vivo CRISPR therapies targeting common cardiometabolic diseases, with lead program STX-1150 in first-in-human study.
  • Key competitors: Amgen; Sanofi/Regeneron; Novartis; Verve Therapeutics; CRISPR Therapeutics; Editas; Intellia; Ionis; Arrowhead; Lilly/Prevail and others.
  • Industry trends: Shift toward one-time genetic medicines, focus on long-term adherence and durability, growing attention to Lp(a) and triglycerides as key, undertreated drivers of risk.

Operational Metrics

  • Customers: Collaboration revenue is derived from partnerships with Sanofi and Lilly/Prevail; no commercial product revenue to date
  • Locations: Headquarters in Alameda, California; manufacturing via third-party CDMOs
  • Geographic presence: U.S. operations; initial clinical trial for STX-1150 cleared by the Australian TGA
  • Partnerships: Sanofi (upfront $40M; up to $410M dev/reg milestones and $825M commercial milestones plus royalties); Lilly/Prevail (upfront $45M; up to $110M dev/reg and $1.1B commercial milestones plus royalties); Acuitas LNP license; UCB foundational IP license
  • Orders/GMV: Not applicable (pre-commercial biotech)
  • Other key metrics: 89 employees as of March 31, 2026; three in vivo candidates (STX-1150, STX-1200, STX-1400); CIRM grants up to ~$25.7M; first-in-human trial targets up to 64 adults with elevated LDL-C

Financials Highlights

  • Revenue (current): $51.2 million collaboration revenue (2025)
  • Revenue growth: Up 87% year over year (from $27.4 million in 2024)
  • Operating income: Loss from operations of $(26.1) million (2025)
  • Net income: Net loss of $(21.8) million (2025)

Management

  • Benjamin L. Oakes, Ph.D., President and Chief Executive Officer - Company co-founder with deep expertise in CRISPR and molecular engineering; previously an Entrepreneurial Fellow at the Innovative Genomics Institute.
  • Svetlana Lucas, Ph.D., Chief Operating Officer - More than 20 years of strategy, commercialization, and BD leadership at companies including Tizona Therapeutics, Amgen/Onyx; also a director at Jasper Therapeutics and aTyr Pharma.
  • David L. Parrot, M.B.A., Chief Financial Officer - Over 25 years in life sciences investment banking at Barclays, SunTrust, BMO Capital Markets, and Piper Jaffray, advising on capital raises and strategic transactions.

IPO Structure

  • Issuer: Scribe Therapeutics Inc.
  • Filing date: July 24, 2026
  • Proposed ticker: SCTX
  • Exchange: Nasdaq Global Market
  • Price range: $15.00 per share
  • Offering size: $128.7 million (gross)
  • Shares offered: 8,580,000 shares (with a 1,287,000-share over-allotment option)
  • Lead underwriters: Leerink Partners; Goldman Sachs & Co. LLC; Guggenheim Securities; Wells Fargo Securities
  • Use of proceeds: Approx. $122.8M net to advance STX-1150 Phase 1 ($30–35M), STX-1400 through IND-enabling and early clinical ($15–20M), STX-1200 through IND-enabling and early clinical ($15–20M), platform and pipeline ($20–25M), and working capital.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.